Roughly two thirds of Americans over 71 have some degree of hearing loss. Fewer than a third of them use a hearing aid.
That gap has held steady for long enough that researchers have spent years trying to account for it. Cost explains part of it. So does the ordinary friction of fitting, adjusting and maintaining a small device. But a persistent thread in the literature is something less practical. A scoping review of hearing loss stigma published in 2025 found that the dominant theme reported by older adults was the fear of being seen as, in their words, old or senile. A Forbes Health consumer survey found that 48 percent of people with hearing loss believed a stigma attached to wearing an aid, and that 46 percent of those diagnosed with hearing loss did not wear one regularly.
It is easy to read that as vanity. The research does not support that reading especially well. What people tend to describe is closer to a calculation about how they expect to be treated once they are visibly marked as declining. It is also worth noting that the predictive power of stigma is inconsistent across studies. One analysis found it accounted for only about 8 percent of the variability in whether someone took up a hearing aid. Stigma is part of the picture, not the whole of it.
What has changed is the stakes attached to that decision. Over the past decade, untreated hearing loss has moved from the margins of dementia research to the center of it.
What the Lancet Commission actually claims
The 2024 report of the Lancet Commission on dementia prevention, intervention and care, led by Gill Livingston and published on 31 July 2024, identified 14 modifiable risk factors that between them are associated with around 45 percent of dementia cases worldwide. Hearing impairment accounts for 7 percent of cases, placing it level with high LDL cholesterol as the single largest contributor on the list.
That figure deserves unpacking, because it is routinely reported in a stronger form than it can bear. Seven percent is a population attributable fraction. It is a modeled estimate of the share of dementia cases that might be avoided if the risk factor were removed entirely from the population, and it holds only if the association between hearing loss and dementia is genuinely causal. That condition is doing a great deal of work, and the Commission is explicit that it is an assumption rather than a settled finding.
The Commission did report that the evidence for treating hearing loss had strengthened since its previous report four years earlier, following new meta-analyses and recalculated attributable fractions.
The proposed mechanisms
Three explanations are usually offered for how hearing loss might affect the brain, and they are not mutually exclusive.
The first is cognitive load. When speech is degraded, the brain diverts resources toward decoding the sound, leaving less available for encoding what was actually said. Over years, the argument runs, that sustained reallocation has a cost.
The second is social withdrawal. Conversation becomes effortful, then unrewarding, then avoided. Reduced social contact is itself associated with higher dementia risk, although the size of that association is contested. The Lancet Commission’s pooled estimate for infrequent social contact is a 57 percent increase in relative risk. Several independent meta-analyses of social isolation and loneliness report smaller effects, in the range of 23 to 34 percent. Any process that drives isolation inherits whichever of those figures turns out to be nearer the mark.
The third is structural. Studies of brain imaging have reported altered connectivity and accelerated atrophy in people with hearing loss, including at early stages, which may lower the threshold at which underlying pathology becomes clinically visible.
All three are plausible. None has been demonstrated to be the operative mechanism in humans, and the imaging findings in particular are observational.
What happened when it was actually tested
The strongest test to date is the ACHIEVE trial, led by Frank Lin and published in The Lancet in 2023. It randomized 977 adults aged 70 to 84 with untreated mild to moderate hearing loss to either a hearing intervention or a health education control, and followed them for three years.
The headline result was negative. Across the full study population, hearing intervention did not slow cognitive decline.
The detail beneath it is where the interest lies. Participants had been recruited from two very different streams. Some 739 were healthy community volunteers who came forward for the study. The other 238 were drawn from the long-running Atherosclerosis Risk in Communities cohort, and they carried more cardiovascular risk factors, had lower baseline cognitive scores, and declined faster over the three years. In that subgroup, hearing intervention was associated with a 48 percent slowing of cognitive decline. Among participants in the top quartile of predicted risk, the figure was 62 percent.
This is a prespecified subgroup analysis rather than a primary endpoint, and subgroup findings warrant more caution than headline results. The reasonable reading is not that hearing aids protect the brain. It is that they may do more for people who were already declining than for people who were not.
The 2026 evidence, and a finding worth acting on
A pooled analysis of seven cohorts across 33 countries, published in Cell Reports Medicine in May 2026, found that hearing aid users had about 9 percent lower risk of probable dementia than non-users with hearing loss.
Nine percent is a modest effect. But the analysis contained something more useful than its headline. Participants who rated their own hearing aids as fair or poor showed no significant difference in risk compared with people who wore no aid at all. The benefit, such as it is, appears to depend on the device working well rather than merely existing.
Timing may matter too. An analysis of nearly 3,000 participants in the Framingham Heart Study, led by Lily Francis with senior author Sudha Seshadri and published in JAMA Neurology on 18 August 2025, reported substantially lower dementia risk among hearing aid users who began before age 70, with a hazard ratio of 0.39 and a 95 percent confidence interval running from 0.17 to 0.89. There was no significant reduction among those who started at 70 or later. That confidence interval is wide, which is what a modest number of events in a subgroup looks like, and the point estimate should be read with that in mind.
The case for caution
A 2026 review by Natascha Merten, Piers Dawes, Kevin Munro and Willa Brenowitz set out four alternative explanations that could generate the observed association without hearing loss causing anything: measurement error, common causes such as vascular disease and biological aging affecting both systems, reverse causation, and selection bias arising from who survives to be studied.
Reverse causation is the one that will not go away. Dementia has a prodromal period lasting years, and early neurodegeneration can impair the central processing of sound. Hearing difficulty may therefore be an early sign of the disease rather than a contributor to it. Long-duration cohort studies have made this less likely as a complete explanation, but it cannot be excluded.
What a reader can reasonably take from this
The association between untreated hearing loss and dementia is consistent, large and now well replicated. Whether it is causal is not settled, and the one large randomized trial designed to test it did not find an overall effect.
That is a weaker claim than the one usually made in headlines. It is still a substantial one. Treating hearing loss carries little risk, improves daily life on its own terms, and may plausibly help the people at highest risk. The evidence also suggests that a poorly fitted aid left in a drawer is close to no aid at all, which makes follow-up care the part of this worth taking seriously.
Anyone weighing the decision should discuss it with an audiologist or physician who can assess their own hearing and their own risk.